Myriad CDx IDs patients with metastatic pancreatic cancer

Create PDF

August 2019—Myriad Genetics announced that its BRACAnalysis CDx companion diagnostic test effectively identified patients with metastatic pancreatic cancer who benefitted from treatment with olaparib (Lynparza, AstraZeneca) in the phase three POLO study. Results of the study were presented at the 2019 American Society of Clinical Oncology annual meeting in Chicago.

The study demonstrated that patients with a germline mutation and whose disease had not progressed on first-line platinum-based chemotherapy had a clinically meaningful and statistically significant improvement in progression-free survival of 7.4 months when treated with Lynparza compared with 3.8 months for placebo (HR, 0.53; P, 0.004).